Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cyclophosphamide + celecoxib + methotrexate
- Development stage
- Unknown
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
This is a combination regimen of three small-molecule drugs—cyclophosphamide, celecoxib, and methotrexate—used in metronomic (continuous low-dose) chemotherapy protocols. Cyclophosphamide is an alkylating agent that crosslinks DNA, leading to cell death; methotrexate is an antimetabolite that inhibits dihydrofolate reductase, blocking DNA synthesis; and celecoxib is a selective cyclooxygenase-2 (COX-2) inhibitor with anti-inflammatory and potential antiangiogenic properties. The combination has been investigated primarily for its antiangiogenic effects in advanced cancers and relapsed or refractory lymphomas. The regimen aims to suppress tumor growth by targeting both cancer cells directly (cytotoxicity) and the tumor microenvironment (antiangiogenesis), with generally good tolerability at low doses[1][2].
- Other names
- methotrexatemetronomic cyclophosphamide, celecoxib, and methotrexate regimenCytophosphan + Celecoxib + Methotrexate
02
Targets
PTGS2 (Prostaglandin-Endoperoxide Synthase 2)DHFR (Dihydrofolate reductase)DNA
Beyond the preview
Go deeper on cyclophosphamide + celecoxib + methotrexate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cyclophosphamide + celecoxib + methotrexate.